PVIVAX

Knowledge sharing for relapsing malaria

Search

  • P. vivax malaria
    • Malaria and P. vivax malaria
    • Symptoms & severity
    • Illness and mortality
    • Populations at risk
      • Pregnant women and children
      • Migratory populations
    • Role in malaria elimination
    • Lifecycle
    • Relapses
    • Vectors
  • Diagnosis & treatment
    • Diagnostic methods
      • Microscopy
      • Rapid diagnostic tests
      • Molecular methods & serology
    • Diagnosing severe vivax malaria
    • Treatment
      • Radical cure
      • Blood stage treatment
      • Liver stage treatment
    • G6PD Deficiency
      • G6PD Global Prevalence
      • G6PD diagnostics
      • Types of G6PD clinical diagnostic tests
  • Regions & countries
    • Africa
    • Eastern Mediterranean
    • South East Asia
    • The Americas
    • Western Pacific
  • In the field
    • Projects
    • Stories and Videos
  • Tools
    • Study database
  • Resources
  • News & events
  • About us
Map with highlighted countries to indicate where studies are taking place

P. vivax malaria studies:  A database of studies focusing on improving access to radical cure.

View the database

Photo: istock

About the P. vivax information hub. 

Find out more
Photo: istock

Featured resources

River landscape with boats

The Partnership for Vivax Elimination (PAVE)

The Partnership for Vivax Elimination (PAVE) supports countries in adopting new and existing tools and approaches to achieve universal access to the best clinical practices for P. vivax case management.
top corner of document zoomed in
05 Aug 2021

New treatment for P. vivax malaria may benefit Brazilian public health

This briefing provides an overview of the population-level transmission dynamics modelling study by Nekkab et al. on the estimated impact of tafenoquine (TQ) on control and elimination of P. vivax malaria in Brazil. The briefing is available in English, Spanish and Portuguese. 

la Alianza para la eliminación de vivax (PAVE, por sus siglas en inglés)
Fact sheet
Healthworker and patient in a consultation

Partnership for Vivax Elimination (PAVE) Feasibility Studies and Operational Research

PAVE is conducting feasibility studies and operational research to support Ministries of Health in malaria endemic countries to look at the best way to use different P. vivax relapse treatments and diagnostics at different levels of the healthcare system in support of their elimination goals.
young man and woman sitting on a bench outside health clinic

the Tafenoquine Roll-out STudy (TRuST)

The Brazilian Ministry of Health (MoH) and MMV, are conducting a study to understand the feasibility of providing appropriate radical cure treatment (primaquine - PQ - or tafenoquine – TQ) based on the results of G6PD testing conducted in real-world settings. 
1

News

Speakers at the Symposium

Exploring new tools for P. vivax elimination in Brazil

01 Jun 2022
children sitting under a mosquito bed net.

Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration

14 Mar 2022
quote and photo of person quoted

P. vivax radical cure in Latin America: regional coordination to advance malaria elimination

17 Dec 2021
microbiology laboratory in Porto Velho, Brazil

First real-world use of new protocol for P. vivax case management in Brazil – a Health Ministry and MMV collaboration

08 Oct 2021
View news and events
1

Events

1

Publications

18 May 2022

Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA)

This is the write up of a multicentre, health care facility-based, randomized, controlled, open-label trial in Bangladesh, Indonesia and Ethiopia. The study evaluated the potential benefit of a universal radical cure for both P. vivax and P. falciparum in different endemic locations. 

Trials
Peer-reviewed article
22 Feb 2022

Community engagement for malaria elimination in the Greater Mekong Sub-region: a qualitative study among malaria researchers and policymakers

This article explores the perspectives of researchers and policy makers in the Greater Mekong Sub-region (GMS) on community engagement for malaria control and elimination. 

Malaria Journal
Peer-reviewed article
Available online 3 December 2021

Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

Single-dose tafenoquine 300 mg is approved for Plasmodium vivax malaria relapse prevention in patients at least 16 years old. We aimed to determine appropriate oral tafenoquine paediatric dosing regimens, including a dispersible formulation, and evaluated tafenoquine efficacy and safety in children infected with P. vivax.

Lancet Child & Adolescent Health
Peer-reviewed article
30 Oct 2021

Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria

This study aimed to map out the national antimalarial policy processes in seven endemic countries to identify areas where it can be improved to align with best practices and optimal efficiency.

Malaria Journal
Peer-reviewed article
View all publications

Get in touch

Contact us.

Submit information

Subscribe

Follow us

  • Twitter
  • LinkedIn
  • Facebook
  • Disclaimer
  • Privacy policy
A Remora website by Manta Ray Media